Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
April 04, 2018 09:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the presentation of a...
Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update
March 29, 2018 08:10 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 29, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics to Present at Two International Conferences in March
March 09, 2018 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 09, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber,...
Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
March 08, 2018 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 08, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold...
Galectin Therapeutics to Present at 30th Annual ROTH Conference
February 28, 2018 16:35 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber,...
Galectin Therapeutics to Present at BIO CEO & Investor Conference
February 06, 2018 09:15 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber,...
Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
January 25, 2018 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat non-alcoholic steatohepatitis...
Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial
November 13, 2017 08:30 ET
|
Galectin Therapeutics Inc.; Providence Cancer Institute
NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today...
Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma
September 07, 2017 08:10 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung Cancer
July 19, 2017 10:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., July 19, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that the Big Ten Cancer Research Consortium has begun patient dosing in a Phase 1b/2 clinical study to...